FilingSEC EDGAR8-K
Keros Therapeutics Reports Q3 Profit and Phase 2 Clinical Progress
· SEC accepted
StagePhase 2
Filing content
Keros Therapeutics reported a net income of $14.2 million for Q3 2026 driven by license revenue from Takeda and announced the first patient dosed in its Phase 2 trial for rinvatercept.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…